在实验小鼠模型中对帕拉米韦抗H7N9禽流感病毒特性的评估。
Assessment of Antiviral Properties of Peramivir against H7N9 Avian Influenza Virus in an Experimental Mouse Model.
作者信息
Farooqui Amber, Huang Linxi, Wu Suwu, Cai Yingmu, Su Min, Lin Pengzhou, Chen Weihong, Fang Xibin, Zhang Li, Liu Yisu, Zeng Tiansheng, Paquette Stephane G, Khan Adnan, Kelvin Alyson A, Kelvin David J
机构信息
Division of Immunology, International Institute of Infection and Immunity, University Health Network & Shantou University Medical College, Shantou, China Division of Experimental Therapeutics, Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada Guangdong Provincial Key Laboratory of Infectious Diseases and Molecular Immunopathology, Shantou, Guangdong, China.
Infectious Diseases Department, The First Affiliated Hospital of Shantou University Medical College, Shantou, China.
出版信息
Antimicrob Agents Chemother. 2015 Dec;59(12):7255-64. doi: 10.1128/AAC.01885-15. Epub 2015 Sep 14.
The H7N9 influenza virus causes a severe form of disease in humans. Neuraminidase inhibitors, including oral oseltamivir and injectable peramivir, are the first choices of antiviral treatment for such cases; however, the clinical efficacy of these drugs is questionable. Animal experimental models are essential for understanding the viral replication kinetics under the selective pressure of antiviral agents. This study demonstrates the antiviral activity of peramivir in a mouse model of H7N9 avian influenza virus infection. The data show that repeated administration of peramivir at 30 mg/kg of body weight successfully eradicated the virus from the respiratory tract and extrapulmonary tissues during the acute response, prevented clinical signs of the disease, including neuropathy, and eventually protected mice against lethal H7N9 influenza virus infection. Early treatment with peramivir was found to be associated with better disease outcomes.
H7N9流感病毒可导致人类患上严重疾病。神经氨酸酶抑制剂，包括口服的奥司他韦和注射用的帕拉米韦，是此类病例抗病毒治疗的首选药物；然而，这些药物的临床疗效存在疑问。动物实验模型对于理解抗病毒药物选择性压力下的病毒复制动力学至关重要。本研究证明了帕拉米韦在H7N9禽流感病毒感染小鼠模型中的抗病毒活性。数据显示，在急性反应期间，以30毫克/千克体重重复给予帕拉米韦成功地从呼吸道和肺外组织中清除了病毒，预防了包括神经病变在内的疾病临床症状，并最终保护小鼠免受致命的H7N9流感病毒感染。研究发现，早期使用帕拉米韦治疗与更好的疾病转归相关。
Zotero 插件